OTC •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/19/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeOTC
Market Capitalization17,832 mln
Float222 mln
Earnings Date07/16/2026
EPS
0.14
Overpriced
P / E
164
Highly speculative
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-2.62
Likely reliable
Relative Strength
80
/ 100
Strongly outperforming
Debt / Equity
0.47
Low leverage
Business Description
Swedish Orphan Biovitrum (Sobi) is a Swedish pharmaceutical company founded in 1939 and based in Stockholm, serving patients across Europe, North America, the Middle East, Asia, and Australia. The company focuses on rare and serious diseases, offering a broad range of specialty medicines that treat conditions such as haemophilia, immune disorders, and certain blood cancers. Sobi works alongside partners including Sanofi, Apellis Pharmaceuticals, and ADC Therapeutics to develop and deliver these treatments to patients who have few or no other options.
